Related Experiment Videos
Interferon-alpha treatment for chronic hepatitis C in children
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
The Turkish Journal of Pediatrics
|March 25, 2000
Summary
Recombinant interferon-alpha therapy shows promise for treating chronic hepatitis C in children. Six months of treatment resulted in a 50% complete response rate, though patients with prior malignant diseases were less responsive.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Virology
Background:
- Chronic hepatitis C is a significant health concern.
- Interferon-alpha is a standard treatment for adults but data in children is limited.
- Pediatric chronic hepatitis C requires effective therapeutic options.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant interferon-alpha therapy in children with chronic hepatitis C.
- To determine optimal treatment duration and identify patient subgroups.
- To assess long-term outcomes after therapy cessation.
Main Methods:
- A study involving 10 children diagnosed with chronic hepatitis C.
- Treatment with recombinant interferon-alpha at 5 million units/m2 body surface, three times weekly for six months.
- Monitoring of aminotransferase levels, HCV-RNA, and antibody status.
Main Results:
- At therapy completion, 50% (5/10) achieved complete response, and 2/10 had partial response.
- After six months post-therapy, 4/8 patients (50%) maintained complete response.
- Non-responders were exclusively patients with prior malignant diseases.
Conclusions:
- Recombinant interferon-alpha therapy is beneficial for pediatric chronic hepatitis C.
- A six-month treatment course appears reasonable for this population.
- Children with a history of malignant diseases may not be suitable candidates for interferon-alpha treatment.